You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Viatris Inc.'s $36.50 per share offer for Pacira BioSciences, Inc. faces two stockholder complaints and fifteen demand letters alleging merger disclosures omitted or misrepresented material information.
VEATRIS reported Q3 revenue of $3.75 billion, adjusted EBITDA of $1.2 billion and adjusted EPS of $0.71, and raised 2026 guidance midpoints; the proposed Pacera acquisition is expected to close before the end of November.
Viatris agreed to acquire Pacira for $36.50 per share in cash, an aggregate equity value of $1.65 billion. The transaction is expected to close by the end of November 2026.
Viatris Inc. reported third-quarter 2026 total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion, and raised 2026 guidance midpoints; the Pacira BioSciences acquisition is expected to close by the end of November 2026.
Viatris subsidiary Peach Purchaser Sub Inc. began a $36.50 per share cash tender offer for all Pacira BioSciences, Inc. shares. The offer expires one minute after 11:59 P.M., Eastern Time, on November 16, 2026; payment is expected November 17, 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Viatris raised 2026 guidance, improved adjusted profitability and free cash flow, delivered strong Greater China and North America growth, generated new-product revenue, and advanced recent launches, approvals and the Pacira acquisition. Risks included a wider GAAP loss, Nashik supply constraints, moderating China growth, regional declines, competition and Japanese pricing pressure, and 2027 exclusivity losses.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net sales - Greater China | $702.6M | FY2026 Q3 | +14.2% |
|
|
|||
| Adjusted EBITDA non-GAAP | 4.4B | Twelve Months Ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $1.28 | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Margin non-GAAP | 56.8% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margins non-GAAP | 57% | the three months ended June 30, 2026 filing | — |
| Capital returned to shareholders | $550M | Through August 5, 2026 | — |
| Consolidated total revenues at constant currency non-GAAP | $3.71B | the three months ended June 30, 2026 filing | — |
| Free Cash Flow non-GAAP | $677.4M | Six Months Ended June 30, 2026 | — |
| Gross debt to adjusted EBITDA non-GAAP | 2.9 | Twelve Months Ended June 30, 2026 | — |
| Net sales - Developed Markets | $2.19B | the three months ended June 30, 2026 filing | — |
| Net sales - Emerging Markets | $542.3M | the three months ended June 30, 2026 filing | — |
| Net sales - JANZ | $296.1M | the three months ended June 30, 2026 filing | — |
| Net sales within North America | 882.7M | the three months ended June 30, 2026 filing | — |
| New product revenues | $172M | Six Months Ended June 30, 2026 | — |
| Share repurchases | $270M | Through August 5, 2026 | — |
| Total net sales | $3.75B | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTRS
this stock
Viatris Inc
|
$23.87B | +67.2% | -3.0% | — | 3.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Viatris Inc.'s $36.50 per share offer for Pacira BioSciences, Inc. faces two stockholder complaints and fifteen demand letters alleging merger disclosures omitted or misrepresented material information.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTRS | +4.6% | +11.6% | +28.0% | +9.4% | +67.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.0% | +12.8% | +27.5% | +9.6% | +56.6% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
